



Amitiza® (lubiprostone) – First-time authorized brand alternative

- On January 4, 2021, [Par launched](#) an authorized brand alternative of Sucampo/Takeda's [Amitiza \(lubiprostone\)](#) capsules.
- Amitiza is approved for the treatment of chronic idiopathic constipation in adults; opioid-induced constipation in adult patients with chronic non-cancer pain; and irritable bowel syndrome with constipation.
- According to IQVIA™, Amitiza sales were approximately \$427 million for the 12 months ended September 30, 2020.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.